What medication can close a PDA?

Medications Used to Close a Patent Ductus Arteriosus in Newborns

When a premature infant is diagnosed with a hemodynamically significant patent ductus arteriosus (hs-PDA)—a condition where the blood vessel connecting the pulmonary artery and aorta fails to close after birth—doctors often turn to medication as a first-line treatment. One of the most effective and commonly used approaches involves nonsteroidal anti-inflammatory drugs (NSAIDs), particularly indomethacin and ibuprofen.

These medications work by inhibiting the production of prostaglandins, substances that keep the ductus arteriosus open. By reducing prostaglandin levels, NSAIDs help promote closure of the vessel. Indomethacin has been used for decades in neonatal intensive care units, while ibuprofen has gained popularity more recently due to a potentially better safety profile, especially concerning kidney function.

Pharmacological treatment with NSAIDs successfully closes the PDA in approximately 70% to 85% of cases. This success rate makes it a preferred option before considering more invasive procedures like surgical ligation or catheter-based interventions. The response to treatment often depends on the baby’s gestational age, weight, and overall clinical condition.

While effective, these drugs are not without risks. Careful monitoring is essential to avoid potential side effects, such as reduced blood flow to the kidneys or intestines. Still, when used appropriately, NSAIDs remain a cornerstone in the management of hs-PDA, offering a non-surgical path to closure for many fragile newborns.